Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

Phase 3 Recruiting 177 enrolled Joincare Pharmaceutical Group Industry Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.

Timeline

Start: 2025-11-07
Primary completion: 2026-01-31
Completion: 2026-04-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JKN2301	Unknown	—	Oral
Comparator	Oseltamivir	Small molecule	—	Oral

Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

Summary

Timeline

Drugs

Indications